‘The Group Room’ Radio Talk Show Celebrates Three Years on the Air

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 4
Volume 8
Issue 4

LOS ANGELES-“The Group Room,” a nationally syndicated cancer radio talk show, entered its third year on the air with new markets, accolades for its host Selma Schimmel, and a new book based on the show.

LOS ANGELES—“The Group Room,” a nationally syndicated cancer radio talk show, entered its third year on the air with new markets, accolades for its host Selma Schimmel, and a new book based on the show.

The recently signed new markets are in Alabama, Florida, Idaho, Pennsylvania, and Tennessee. The book is called Cancer Talk, and the honor for Ms. Schimmel is being named one of the “Heavy Hundred” by the radio industry publication Talkers Magazine. The “Heavy Hundred” represent the most important radio talk show hosts in America. Ms. Schimmel is a 16-year breast cancer survivor and founder of Vital Options, the national cancer support, advocacy, and communications organization.

“It is an honor to receive this recognition, especially when you consider that there are 4,500 talk shows nationwide,” Ms. Schimmel said. “I want to acknowledge Premiere Radio Networks and our founding sponsor, Bristol-Myers Squibb; corporate sponsors Ortho Biotech and Pharmacia & Upjohn; and the hundreds of local supporters and radio stations who make this show possible every week.”

The program airs live each Sunday from 4 to 6 pm Eastern Daylight Time in major markets and can also be heard live on the Internet at www.vitaloptions.org.

Cancer Talk, a book of hope and lessons in endurance culled from conversations on the radio show, was written by Ms. Schimmel and is due out this spring from Broadway Books, a division of Random House.

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content